Finland is Developing a Model for the Assessment and Reimbursement of Digital Therapies
Finland is developing a model to streamline the adoption of digital healthcare solutions.
As summer approaches, it’s a great time to pause, reflect, and appreciate the progress we’ve made together.
This spring marked my first full year at Medaffcon, and what a journey it has been. I’m proud to say we’ve had a strong start to the year, and our momentum continues to build across our teams and capabilities.
One of the highlights has been the growth of our Nordic operations. We’ve successfully completed our first cross-border projects and continue to invest in our Swedish presence. Medaffcon AB has recently moved into the Forskaren innovation hub in Stockholm – a vibrant environment that supports our ambition to expand and collaborate. Our Swedish team is also growing, with new talent joining us to meet the increasing demand.
Internally, the stability in our teams has been a welcome shift after last year’s changes. Medaffcon remains a highly attractive employer – a fact reflected in the impressive number of job applications we continue to receive.
This May’s summer day event brought us all together, strengthening our team spirit and reminding us of the strong culture we’re building.
We’re also committed to continuous learning and development. Our internal competence development initiatives are moving ahead ensuring we grow not only as a company but as individuals.
Looking ahead, we’re already deep into preparations for this autumn’s EMMA event – our flagship forum for thought leadership and industry dialogue. It promises to be another exciting chapter for Medaffcon.
Wishing you a relaxing and sunny summer!
Warm regards,
Heikki Koski
CEO, Medaffcon
Finland is developing a model to streamline the adoption of digital healthcare solutions.
The Swedish Health Economics Association (SHEA) held its annual conference, offering valuable insights into key topics in health economics.
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.